MVA-BN® Anthrax
Bavarian Nordic is developing an
anthrax vaccine based on MVA-BN®. This would be a combined
anthrax and smallpox prophylactic vaccine and would build upon the
Company's existing ability to manufacture MVA-BN® at an
industrial GMP (Good Manufacturing practice) scale.
An MVA-BN® anthrax vaccine could
potentially have the following advantages:
- Combined smallpox and anthrax vaccine - one vaccine to offer
protection against two of the largest biological threats
- Improved safety suitable for high risk groups
- Reduced number of vaccinations compared to the current licensed
anthrax vaccine
- Validated manufacturing process for MVA-BN® based
vaccine
- Improved storage and transport logistics of a freeze-dried
formulation
